What Is Gastrin-Releasing Peptide? Definition and What Research Reports
Gastrin-releasing peptide (GRP) is a small signalling peptide of the bombesin-like peptide family, found in gut tissue and in nerve cells, that acts on a G-protein-coupled receptor called GRPR. In the published literature the term appears mainly in three contexts: receptor pharmacology and binding studies, neuroscience work on spinal and brain circuits, and oncology, where a precursor fragment (ProGRP) has been studied as a blood marker and GRPR as a tumour-targeting handle. This entry is definitional only.
Gastrin-releasing peptide (GRP) is a small, naturally occurring signalling peptide — a neuropeptide and gut peptide — that belongs to the bombesin-like peptide family and exerts its effects by binding a G-protein-coupled receptor known as the gastrin-releasing peptide receptor (GRPR). It is produced in the body rather than being a synthetic research compound in origin: it is expressed in enteric and central nervous system neurons and in neuroendocrine cells, and it is released locally to act on nearby GRPR-bearing cells. Its name reflects the context in which it was first characterised, gastric physiology and the hormone gastrin, but most modern literature that uses the term is not about the stomach at all. In peptide research, "gastrin-releasing peptide" is used as the name of the endogenous ligand, while "GRPR" or "BB2 receptor" names its target, and "ProGRP" names a fragment of the precursor protein measured in blood.
This page is for educational purposes only and is not medical advice; consult a licensed physician or qualified clinician about any health decision. Nothing here describes how any substance should be used, and no dosing information is provided.
What class of molecule is it?
GRP is a peptide hormone/neurotransmitter, not a steroid, not a small-molecule drug and not an antibody. Functionally it is classified within the bombesin-like peptide family, a group whose comparative biology has itself been a research subject: a 2021 Scientific Reports paper re-examined the GRP/bombesin system using Xenopus in a reverse-evolutionary analysis and reported a revised picture of how the frog-derived peptide bombesin relates to mammalian GRP and its receptors (PMID 34172791). Because bombesin and GRP share receptor preferences, older pharmacology papers often use "bombesin-like" and "GRP" in overlapping ways, which is worth knowing when reading across decades of literature.
The receptor: where the term GRPR comes in
Most laboratory work on GRP is really work on the GRP–GRPR pair. A 2005 study in Biochemical Pharmacology set out to identify the key amino acids in GRPR responsible for the high-affinity binding of GRP, and the researchers used receptor mutagenesis to map which residues contributed to that binding interaction (PMID 15670577). A separate 2008 paper in the same journal examined what happens after the receptor is engaged, reporting on the function of non-visual arrestins in the signalling and endocytosis (internalisation) of the GRP receptor (PMID 18199425). Together these are the kind of papers a reader will encounter if they search the term expecting basic receptor pharmacology rather than clinical material.
Quick glossary of related terms
| Term | What it refers to in the literature |
|---|---|
| GRP | The endogenous gastrin-releasing peptide itself; the ligand. |
| GRPR (BB2) | The G-protein-coupled receptor GRP binds; the subject of binding and internalisation studies (PMID 15670577). |
| ProGRP | A stable fragment of the GRP precursor measured in serum and studied as a tumour marker (PMID 35737164). |
| Bombesin / bombesin-like peptides | The wider peptide family GRP sits within, re-analysed in a 2021 comparative study (PMID 34172791). |
| GRPR antagonism | Experimental blockade of the receptor, used as a tool in animal physiology studies (PMID 41173109). |
Doing the math on a vial? The PeptideU app does reconstitution, units and dilution for you.
Try it freeHow the term is used in peptide research
1. As a cancer biomarker (ProGRP)
The most clinically visible use of the term is not GRP itself but its precursor fragment. A 2022 paper in Bulletin of Experimental Biology and Medicine examined pro-gastrin-releasing peptide as a marker of small cell lung cancer (PMID 35737164), and a 2023 review in Cancers assessed ProGRP as a biomarker across lung neuroendocrine neoplasms, where the authors summarised its reported role in diagnosis and monitoring (PMID 37444393). In this context GRP is of interest because neuroendocrine tumour cells produce it, so the circulating precursor acts as a readout of tumour biology rather than as something administered.
2. As a receptor target for imaging and delivery
Because GRPR is over-expressed on some tumour cells, GRP-derived sequences are used as targeting elements. A 2019 Nanomedicine study described GRPR-targeted hybrid peptide/phospholipid delivery systems built to carry pDNA and siRNA into receptor-expressing cells, and the researchers characterised those constructs in laboratory models (PMID 31050581). Related expression work continues in other tumour types: a 2024 report in ESMO Gastrointestinal Oncology examined gastrin-releasing peptide receptor expression in gastrointestinal stromal tumours (PMID 41646945).
3. As a neurotransmitter in sensory and motivational circuits
In neuroscience the term appears in spinal cord and brain circuit papers. A 2022 study in Molecular Pain investigated an analgesic effect of gastrin-releasing peptide in the dorsal horn of the spinal cord, a region central to sensory processing (PMID 35815426). Further upstream, a 2025 Nature Communications paper reported that GRP signalling in the medial shell of the nucleus accumbens regulated neuronal excitability and motivated behaviour in rodents (PMID 41120321). These are mechanistic animal and tissue studies, not human trials of an administered peptide product.
4. As a cardiovascular and vascular signalling molecule
A smaller strand of literature places GRP in blood-pressure and vascular biology. A 2025 Neurochemistry International study reported that gastrin-releasing peptide acting in the paraventricular nucleus of the hypothalamus exerted hypertensive effects in a preeclampsia model (PMID 40460928), while a companion line of work in Toxicology and Applied Pharmacology reported that GRP receptor antagonism in the same nucleus exerted antihypertensive effects in two-kidney, one-clip (2K1C) hypertensive rats (PMID 41173109). Outside the brain, a 2020 paper in Cells reported that inhibition of gastrin-releasing peptide attenuated phosphate-induced vascular calcification in experimental models (PMID 32192106).
Safety and Adverse Events: What Studies Report
The verified literature summarised here is overwhelmingly mechanistic, biomarker-based or preclinical, and it does not describe a human safety profile for administered gastrin-releasing peptide. No dosing, tolerability or adverse-event data for people are reported in these papers, and none of them evaluated GRP as a consumer or clinical product. What the animal work does show is that GRP signalling is not physiologically neutral: the study of the paraventricular nucleus in a preeclampsia model reported hypertensive effects of GRP in that brain region (PMID 40460928), and researchers in the 2K1C rat model reported the opposite directional result — lowered blood pressure — when the receptor was blocked (PMID 41173109). Findings of that kind are reported in specific animal models and cannot be read as predictions about humans.
Tracking research? Log entries with dates, lots and notes — records, never plans.
Get the appLimitations when reading GRP literature
- Species and model dependence. Blood-pressure and behavioural findings came from rodent models (PMID 41120321), and comparative work shows the peptide family differs across species (PMID 34172791).
- Ligand versus marker. Oncology papers largely measure ProGRP in serum as a marker (PMID 37444393) rather than studying GRP as something given.
- Receptor-level nuance. Binding affinity and receptor internalisation are separable properties, as the mutagenesis and arrestin studies illustrate (PMID 18199425).
- Direction of effect varies by site. The same peptide has been reported as analgesic in the spinal dorsal horn (PMID 35815426) and as pro-hypertensive in a hypothalamic nucleus (PMID 40460928), so "what GRP does" depends entirely on where.
References
- Function of non-visual arrestins in signaling and endocytosis of the gastrin-releasing peptide receptor (GRP receptor) (Biochemical Pharmacology, 2008)
- Identification of key amino acids in the gastrin-releasing peptide receptor (GRPR) responsible for high affinity binding of gastrin-releasing peptide (GRP) (Biochemical Pharmacology, 2005)
- The gastrin-releasing peptide/bombesin system revisited by a reverse-evolutionary study considering Xenopus (Scientific Reports, 2021)
- Pro-Gastrin-Releasing Peptide as a Marker of Small Cell Lung Cancer (Bulletin of Experimental Biology and Medicine, 2022)
- Pro-Gastrin-Releasing Peptide as a Biomarker in Lung Neuroendocrine Neoplasm (Cancers, 2023)
- Gastrin-releasing peptide receptor expression in gastrointestinal stromal tumours (ESMO Gastrointestinal Oncology, 2024)
- Gastrin-releasing peptide receptor-targeted hybrid peptide/phospholipid pDNA/siRNA delivery systems (Nanomedicine, 2019)
- Analgesic effect of gastrin-releasing peptide in the dorsal horn (Molecular Pain, 2022)
- Gastrin-releasing peptide signaling in the nucleus accumbens medial shell regulates neuronal excitability and motivation (Nature Communications, 2025)
- Gastrin-releasing peptide in the paraventricular nucleus exerts hypertensive effects in preeclampsia (Neurochemistry International, 2025)
- Gastrin releasing peptide receptor antagonism in the paraventricular nucleus exerts antihypertensive effects in 2K1C rats (Toxicology and Applied Pharmacology, 2026)
- Inhibition of Gastrin-Releasing Peptide Attenuates Phosphate-Induced Vascular Calcification (Cells, 2020)
Frequently asked questions
What is gastrin-releasing peptide in one sentence?▾
Gastrin-releasing peptide is a naturally produced signalling peptide of the bombesin-like peptide family that binds a G-protein-coupled receptor called GRPR. Research on the pair spans receptor pharmacology, such as mutagenesis work identifying receptor amino acids responsible for high-affinity GRP binding (PMID 15670577), and studies of receptor internalisation involving non-visual arrestins (PMID 18199425).
Is GRP the same thing as bombesin?▾
No. Bombesin is an amphibian peptide, and GRP is its mammalian counterpart within the same bombesin-like peptide family, which is why older pharmacology papers use the terms interchangeably. A 2021 reverse-evolutionary study using Xenopus re-examined the GRP/bombesin system and reported a revised view of how these peptides and their receptors relate across species (PMID 34172791).
What is ProGRP and how does it differ from GRP?▾
ProGRP is a stable fragment of the gastrin-releasing peptide precursor that can be measured in serum, whereas GRP is the short active peptide itself. Researchers have studied ProGRP as a marker of small cell lung cancer (PMID 35737164) and reviewed its role as a biomarker across lung neuroendocrine neoplasms (PMID 37444393).
Why is GRPR studied in oncology?▾
Because the receptor is expressed on certain tumour cells, it has been examined both as a tissue characteristic and as a targeting handle. A 2024 report described gastrin-releasing peptide receptor expression in gastrointestinal stromal tumours (PMID 41646945), and a 2019 study built GRPR-targeted hybrid peptide/phospholipid systems intended to deliver pDNA and siRNA to receptor-expressing cells (PMID 31050581).
What has research reported about GRP in the nervous system?▾
Neuroscience studies place GRP in sensory and motivational circuits. The study in Molecular Pain investigated an analgesic effect of gastrin-releasing peptide in the spinal dorsal horn (PMID 35815426), while a 2025 Nature Communications paper reported that GRP signalling in the nucleus accumbens medial shell regulated neuronal excitability and motivation in rodents (PMID 41120321).
Does GRP affect blood pressure?▾
In animal models, researchers reported directional effects. One 2025 study reported that gastrin-releasing peptide in the paraventricular nucleus exerted hypertensive effects in a preeclampsia model (PMID 40460928), and separate work reported that GRP receptor antagonism in that nucleus exerted antihypertensive effects in 2K1C rats (PMID 41173109). These are preclinical findings, not human results.
Are there human safety data for administered gastrin-releasing peptide?▾
The literature summarised on this page does not provide a human safety or tolerability profile for administered GRP; the papers are mechanistic, biomarker or animal studies, including vascular work reporting that inhibition of gastrin-releasing peptide attenuated phosphate-induced vascular calcification in experimental models (PMID 32192106). This page is educational only and is not medical advice; consult a licensed physician.
Track it. Calculate it. Actually understand it.
References
This page summarises published research for education — it is not medical advice, and nothing here is a recommendation to use, purchase, or dose any substance. Study parameters described are what researchers reported, not instructions. Consult a qualified clinician before any health decision.